v3.26.1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Millions
6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Operating activities    
Net income $ 4,368 $ 3,180
Adjustments to reconcile net income to net cash provided by/(used in) operating activities:    
Depreciation and amortization 765 411
Noncash lease expense 86 69
Stock-based compensation 621 467
Deferred income tax expense (benefit) (18) (78)
Change in fair value of contingent consideration (538) 172
Other investment gains (62) (433)
Net (gains) losses within CIPs (162) (183)
Net (purchases) proceeds within CIPs (3,107) (1,984)
(Earnings) losses from equity method investees (147) (93)
Distributions of earnings from equity method investees 42 147
Changes in operating assets and liabilities:    
Accounts receivable (333) 114
Investments, trading 190 78
Other assets (1,718) (2,480)
Accrued compensation and benefits (1,411) (1,186)
Accounts payable and accrued liabilities 256 182
Other liabilities 1,415 1,853
Net cash provided by/(used in) operating activities 247 236
Investing activities    
Purchases of investments (753) (434)
Proceeds from sales and maturities of investments 183 230
Distributions of capital from equity method investees 114 262
Net consolidations (deconsolidations) of sponsored investment funds (54) (68)
Acquisitions, net of cash acquired (15) (3,106)
Purchases of property and equipment (215) (167)
Net cash provided by/(used in) investing activities (740) (3,283)
Financing activities    
Repayments of long-term borrowings 0 (796)
Proceeds from long-term borrowings 0 1,080
Dividends/Subco distributions paid (1,906) (1,646)
Proceeds from stock options exercised 88 98
Shares/Subco Units repurchased (1,271) (1,053)
Net proceeds from (repayments of) borrowings by CIPs 132 (29)
Net subscriptions received/(redemptions/distributions paid) from noncontrolling interest holders 2,536 1,716
Other financing activities 0 (5)
Net cash provided by/(used in) financing activities (421) (635)
Effect of exchange rate changes on cash, cash equivalents and restricted cash (62) 398
Net increase/(decrease) in cash, cash equivalents and restricted cash (976) (3,284)
Cash, cash equivalents and restricted cash, beginning of period 11,490 12,779
Cash, cash equivalents and restricted cash, end of period 10,514 9,495
Supplemental schedule of noncash investing and financing transactions:    
Issuance of common shares related to employee stock transactions 867 42
Increase (decrease) in noncontrolling interests due to net consolidation (deconsolidation) of sponsored investment funds $ (1,341) $ (1,192)